nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—KCNH6—forebrain—attention deficit hyperactivity disorder	0.0273	0.0935	CbGeAlD
Terazosin—KCNH7—nervous system—attention deficit hyperactivity disorder	0.0208	0.0712	CbGeAlD
Terazosin—KCNH7—central nervous system—attention deficit hyperactivity disorder	0.02	0.0686	CbGeAlD
Terazosin—KCNH7—cerebellum—attention deficit hyperactivity disorder	0.0196	0.067	CbGeAlD
Terazosin—KCNH7—brain—attention deficit hyperactivity disorder	0.0159	0.0544	CbGeAlD
Terazosin—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.0151	0.0518	CbGeAlD
Terazosin—KCNH6—nervous system—attention deficit hyperactivity disorder	0.0148	0.0507	CbGeAlD
Terazosin—Doxazosin—ADRA2A—attention deficit hyperactivity disorder	0.0144	0.52	CrCbGaD
Terazosin—KCNH6—central nervous system—attention deficit hyperactivity disorder	0.0143	0.0489	CbGeAlD
Terazosin—Prazosin—ADRA2A—attention deficit hyperactivity disorder	0.0133	0.48	CrCbGaD
Terazosin—KCNH6—brain—attention deficit hyperactivity disorder	0.0113	0.0388	CbGeAlD
Terazosin—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.00868	0.0297	CbGeAlD
Terazosin—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.00839	0.0287	CbGeAlD
Terazosin—KCNH2—forebrain—attention deficit hyperactivity disorder	0.00839	0.0287	CbGeAlD
Terazosin—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.00821	0.0281	CbGeAlD
Terazosin—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.00808	0.0277	CbGeAlD
Terazosin—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.0079	0.0271	CbGeAlD
Terazosin—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.00734	0.0252	CbGeAlD
Terazosin—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.00709	0.0243	CbGeAlD
Terazosin—ADRA1B—brain—attention deficit hyperactivity disorder	0.00641	0.022	CbGeAlD
Terazosin—ADRA1D—brain—attention deficit hyperactivity disorder	0.00627	0.0215	CbGeAlD
Terazosin—KCNH2—midbrain—attention deficit hyperactivity disorder	0.00554	0.019	CbGeAlD
Terazosin—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.00471	0.0161	CbGeAlD
Terazosin—KCNH2—nervous system—attention deficit hyperactivity disorder	0.00455	0.0156	CbGeAlD
Terazosin—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.00454	0.0155	CbGeAlD
Terazosin—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.00444	0.0152	CbGeAlD
Terazosin—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.00438	0.015	CbGeAlD
Terazosin—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.00428	0.0147	CbGeAlD
Terazosin—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00368	0.0126	CbGeAlD
Terazosin—ADRA1A—brain—attention deficit hyperactivity disorder	0.0036	0.0123	CbGeAlD
Terazosin—KCNH2—brain—attention deficit hyperactivity disorder	0.00348	0.0119	CbGeAlD
Terazosin—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.00311	0.0107	CbGeAlD
Terazosin—KCNH6—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00297	0.00437	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00297	0.00436	CbGpPWpGaD
Terazosin—ADRA1A—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00268	0.00393	CbGpPWpGaD
Terazosin—KCNH7—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00267	0.00392	CbGpPWpGaD
Terazosin—KCNH7—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00265	0.00389	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00255	0.00375	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00255	0.00374	CbGpPWpGaD
Terazosin—ADRA1B—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00253	0.00372	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00247	0.00363	CbGpPWpGaD
Terazosin—ABCB1—midbrain—attention deficit hyperactivity disorder	0.00243	0.00832	CbGeAlD
Terazosin—KCNH2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00237	0.00349	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00237	0.00349	CbGpPWpGaD
Terazosin—ADRA1A—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00225	0.00331	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00207	0.00304	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00203	0.00298	CbGpPWpGaD
Terazosin—ADRA1D—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00203	0.00298	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00201	0.00296	CbGpPWpGaD
Terazosin—ABCB1—nervous system—attention deficit hyperactivity disorder	0.002	0.00684	CbGeAlD
Terazosin—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00192	0.00659	CbGeAlD
Terazosin—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.00188	0.00644	CbGeAlD
Terazosin—KCNH2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00186	0.00274	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00179	0.00262	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00177	0.00261	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00174	0.00255	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00172	0.00253	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00172	0.00252	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00168	0.00247	CbGpPWpGaD
Terazosin—ADRA1B—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00168	0.00247	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00167	0.00246	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00161	0.00237	CbGpPWpGaD
Terazosin—KCNH2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.0016	0.00236	CbGpPWpGaD
Terazosin—ABCB1—brain—attention deficit hyperactivity disorder	0.00153	0.00523	CbGeAlD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00153	0.00224	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00149	0.0022	CbGpPWpGaD
Terazosin—ADRA1A—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00149	0.0022	CbGpPWpGaD
Terazosin—KCNH2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00149	0.00219	CbGpPWpGaD
Terazosin—KCNH7—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.00149	0.00219	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00148	0.00218	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00147	0.00216	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00146	0.00214	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00144	0.00212	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00141	0.00207	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00135	0.00198	CbGpPWpGaD
Terazosin—KCNH2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00133	0.00195	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00132	0.00194	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00131	0.00192	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00128	0.00188	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00123	0.00181	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0012	0.00177	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00117	0.00171	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00114	0.00168	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00114	0.00167	CbGpPWpGaD
Terazosin—KCNH2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00113	0.00166	CbGpPWpGaD
Terazosin—KCNH2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00112	0.00165	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.00165	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00111	0.00163	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0011	0.00161	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00109	0.0016	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00107	0.00158	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00105	0.00155	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00104	0.00152	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00103	0.00152	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00102	0.0015	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.001	0.00147	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000999	0.00147	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000995	0.00146	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000978	0.00144	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000975	0.00143	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000948	0.00139	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000948	0.00139	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000944	0.00139	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000931	0.00137	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00092	0.00135	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000918	0.00135	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000917	0.00135	CbGpPWpGaD
Terazosin—ADRA1D—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000906	0.00133	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000906	0.00133	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000902	0.00133	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000891	0.00131	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000888	0.0013	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000874	0.00128	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000857	0.00126	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000857	0.00126	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000842	0.00124	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000839	0.00123	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00083	0.00122	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000815	0.0012	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000812	0.00119	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000811	0.00119	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000801	0.00118	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000801	0.00118	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000792	0.00116	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000786	0.00116	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000776	0.00114	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000773	0.00114	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000771	0.00113	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000764	0.00112	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000763	0.00112	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000762	0.00112	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000761	0.00112	CbGpPWpGaD
Terazosin—ADRA1B—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000752	0.00111	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000748	0.0011	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000745	0.0011	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000737	0.00108	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000722	0.00106	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000721	0.00106	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000711	0.00105	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000709	0.00104	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000701	0.00103	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000701	0.00103	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.0007	0.00103	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000699	0.00103	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000693	0.00102	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000687	0.00101	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000679	0.000998	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000678	0.000997	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000676	0.000994	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000673	0.000989	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000668	0.000982	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000668	0.000981	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000665	0.000978	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000653	0.000959	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000633	0.000931	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000632	0.000929	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00062	0.000912	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000618	0.000909	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00061	0.000897	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.0006	0.000882	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000599	0.00088	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000598	0.000878	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000591	0.000868	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000589	0.000865	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000581	0.000855	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000581	0.000855	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000575	0.000845	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000563	0.000828	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000563	0.000827	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000551	0.00081	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000549	0.000807	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000542	0.000796	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000532	0.000782	CbGpPWpGaD
Terazosin—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000523	0.000769	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000523	0.000769	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000518	0.000762	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000516	0.000759	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000516	0.000759	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000511	0.000751	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000507	0.000744	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.0005	0.000736	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.0005	0.000734	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000498	0.000732	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000481	0.000707	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000476	0.0007	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000471	0.000692	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000457	0.000672	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000453	0.000666	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00045	0.000661	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000442	0.00065	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00043	0.000632	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000421	0.000619	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000411	0.000605	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000409	0.000602	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000408	0.000599	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000401	0.000589	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000401	0.000589	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000396	0.000582	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000395	0.000581	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000393	0.000578	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000391	0.000574	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000382	0.000562	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000382	0.000561	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000379	0.000558	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000376	0.000553	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00037	0.000544	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000369	0.000542	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000364	0.000535	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000359	0.000528	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000351	0.000516	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000349	0.000514	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000347	0.00051	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000341	0.000502	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00034	0.000499	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000338	0.000497	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000337	0.000495	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000335	0.000492	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000334	0.000491	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000333	0.000489	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000333	0.000489	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000329	0.000483	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000326	0.00048	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000317	0.000466	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00031	0.000456	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000307	0.000452	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000306	0.00045	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000303	0.000446	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000302	0.000444	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000302	0.000444	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000301	0.000442	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000298	0.000439	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000296	0.000435	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000296	0.000434	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000292	0.000429	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00029	0.000426	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000282	0.000414	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000278	0.000409	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000278	0.000409	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000273	0.000401	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000272	0.0004	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000268	0.000394	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000265	0.00039	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000258	0.00038	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000247	0.000363	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000243	0.000358	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000243	0.000357	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000235	0.000345	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000232	0.000341	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000231	0.000339	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000226	0.000332	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000224	0.000329	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000219	0.000322	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000215	0.000316	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000214	0.000315	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000212	0.000312	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000205	0.000301	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000202	0.000296	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000198	0.000291	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000195	0.000286	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00019	0.00028	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000187	0.000276	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000182	0.000267	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000179	0.000263	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000178	0.000262	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000176	0.000259	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000173	0.000254	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000167	0.000245	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000164	0.000241	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000161	0.000237	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00016	0.000235	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00016	0.000235	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000159	0.000233	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000157	0.000231	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000157	0.00023	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000146	0.000215	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000146	0.000214	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000139	0.000204	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000128	0.000188	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.000179	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000115	0.000169	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000102	0.00015	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	9.7e-05	0.000143	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	9.63e-05	0.000142	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.34e-05	0.000108	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.09e-05	8.96e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.41e-05	7.95e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	4.16e-05	6.11e-05	CbGpPWpGaD
